Sec Form 3 Filing - Choong Ingrid @ Eiger BioPharmaceuticals, Inc. - 2023-08-30

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Choong Ingrid 2. Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [ EIGR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Business Officer (Last) (First) (Middle) C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD. 3. Date of Earliest Transaction (MM/DD/YY) 08/30/2023 (Street) PALO ALTO, CA94306 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 31,100 ( 1 ) D Common Stock 2,400 I By Family Trust ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.37 ( 3 ) 09/23/2023 Common Stock 5,251 D Stock Option (Right to Buy) $ 15.89 ( 3 ) 08/28/2026 Common Stock 7,490 D Stock Option (Right to Buy) $ 11.75 ( 3 ) 03/08/2027 Common Stock 13,200 D Stock Option (Right to Buy) $ 9.5 ( 3 ) 03/13/2028 Common Stock 25,000 D Stock Option (Right to Buy) $ 14.31 ( 3 ) 03/20/2029 Common Stock 17,500 D Stock Option (Right to Buy) $ 10.25 ( 4 ) 09/29/2029 Common Stock 10,000 D Stock Option (Right to Buy) $ 5.6 ( 5 ) 03/11/2030 Common Stock 35,000 D Stock Option (Right to Buy) $ 9.99 ( 6 ) 03/11/2031 Common Stock 60,000 D Stock Option (Right to Buy) $ 8.15 ( 7 ) 07/28/2031 Common Stock 17,500 D Stock Option (Right to Buy) $ 5.1 ( 8 ) 03/10/2032 Common Stock 98,000 D Stock Option (Right to Buy) $ 1.37 ( 9 ) 01/25/2033 Common Stock 25,750 D Stock Option (Right to Buy) $ 1.71 ( 10 ) 02/28/2033 Common Stock 98,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Choong Ingrid C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. PALO ALTO, CA94306 Chief Business Officer Signatures /s/ James Vollins, Attorney-in-Fact for Ingrid C. Choong 09/05/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 3,333 shares underlying Restricted Stock Units ("RSUs") award that will vest in three equal annual installments measured from March 12, 2021, and 10,666 shares underlying RSUs award that will vest in three equal annual installments measured from March 11, 2022. ( 2 )These shares are held directly by the Choong-Dragoli Family Trust, for which the Reporting Person serves as co-trustee. ( 3 )These options are fully vested. ( 4 )The option vests in equal installments over 48 months measured from September 30, 2019, subject to the Reporting Person's continuous service as of each such date. ( 5 )The option vests in equal installments over 48 months measured from March 12, 2020, subject to the Reporting Person's continuous service as of each such date. ( 6 )The option vests in equal installments over 48 months measured from March 12, 2021, subject to the Reporting Person's continuous service as of each such date. ( 7 )The option vests in equal installments over 36 months measured from July 29, 2021, subject to the Reporting Person's continuous service as of each such date. ( 8 )The option vests in equal installments over 48 months measured from March 11, 2022, subject to the Reporting Person's continuous service as of each such date. ( 9 )The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer. ( 10 )The option vests in equal installments over 48 months measured from March 1, 2023, subject to the Reporting Person's continuous service as of each such date.

Remarks: Exhibit List: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.